Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEVEREST-III: Switching to Efavirenz in HIV-infected Children
NCT01146873Phase 3Completed
- Sponsor
- Columbia University
- Start
- Jul 2010
- Primary completion
- Dec 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of efavirenz in human immunodeficiency virus infection (HIV) (4 arms), sponsored by Columbia University. Primary endpoints: Viral Rebound at 48 weeks and Viral Failure at 48 weeks. Started Jul 2010; status: completed.
02
Drugs
efavirenz
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT01146873.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01146873.